Primrose Bio has entered a strategic partnership with ExPLoRNA Therapeutics aimed at advancing the development and marketing of mRNA medicines.
Primrose Bio brings to the partnership its expertise in engineering high-performance RNA polymerases (Prima RNApols), which enhance the yield of mRNA synthesis.
This technology not only reduces the presence of double-stranded RNA (dsRNA) but also lowers production costs, meeting the stringent manufacturing demands for various mRNA applications.
ExPLoRNA Therapeutics specialises in mRNA innovations, focusing on new cap analogues that are crucial for successful protein production.
Its technology boosts protein production, minimises dsRNA formation and reduces in vitro transcription (IVT) costs, offering notable improvements in therapeutic effectiveness.
Primrose Bio CEO Helge Zieler stated: “We are excited to work with ExPLoRNA to bring industry-leading mRNA cap analogs to the market and pairing them with Primrose Bio’s RNA polymerases.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
“This partnership will result in broader manufacturing and design options for companies developing mRNA therapeutics and vaccines, facilitating access to the most efficient capping chemistry available.”
The collaboration between Primrose Bio and ExPLoRNA will lead to the joint development and offering of RNA polymerases and capping compounds that are co-optimised to improve mRNA quality, manufacturing efficiency and the safety and efficacy of therapies.
It intends to offer manufacturing solutions and new design options through advanced capping chemistry to mRNA drug developers.
ExPLoRNA Therapeutics CEO Jacek Jemielity said: “Through joining forces, we’ll advance the mRNA as a modality from the first applications to the next generation.
“We aim at creating the best synergies between our cap analogs and novel polymerases to surpass current manufacturing process and what is achievable with mRNA today.”
In March 2024, Primrose Bio and contract development and manufacturing organisation Intravacc announced a strategic collaboration to enhance conjugate vaccine development and supply.
mRNA vaccine coverage on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
